Literature DB >> 16044359

Intraventricular or lumbar infusion test in adult communicating hydrocephalus? Practical consequences and clinical outcome of shunt operation.

R Bech-Azeddine1, F Gjerris, G Waldemar, M Czosnyka, M Juhler.   

Abstract

BACKGROUND: To investigate the therapeutic consequences of restricting the CSF dynamic evaluation to a lumbar infusion test (LIT), as opposed to our formerly applied intraventricular assessment (VIT), in patients with communicating hydrocephalus (CH).
METHOD: All patients over 18 years of age referred with clinical and radiological indication of treatment-requiring secondary CH (n = 50) or idiopathic normal-pressure hydrocephalus (INPH, n = 33) were subjected to a LIT. Subsequently, a combination of the results of the LIT (mainly the resistance to CSF outflow) and the clinical presentation determined whether to proceed with (a) VIT before a decision about shunt surgery, (b) shunt surgery or (c) no further diagnostic investigation or surgery.
FINDINGS: In 88 percent of the patients with secondary CH and 80 percent of the patients with INPH the decision on shunt surgery was made after performing exclusively a LIT. The shunting success rate was 90 percent in patients with secondary CH and 82 percent in patients with INPH, which however in the latter group decreased to 76 percent, when including the patients undergoing an additional VIT. The achieved shunt success rates are equal or better, compared to the results from previous studies using intraventricular assessment.
CONCLUSIONS: LIT and VIT are equally reliable for selecting shunt responsive patients with CH, using clinical improvement rate as the main criterion for comparison. The practical and economic consequences are substantial: the LIT can be performed in an outpatient setting, whereas VIT necessitates hospitalisation for 1-2 days including occupation of the neurosurgical theatre and postoperative neuro-intensive monitoring.

Entities:  

Mesh:

Year:  2005        PMID: 16044359     DOI: 10.1007/s00701-005-0589-0

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  6 in total

1.  Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting.

Authors:  R Bech-Azeddine; P Høgh; M Juhler; F Gjerris; G Waldemar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

2.  In vitro hydrodynamic properties of the Miethke ProGAV hydrocephalus shunt.

Authors:  David M Allin; Zofia H Czosnyka; Marek Czosnyka; Hugh K Richards; John D Pickard
Journal:  Cerebrospinal Fluid Res       Date:  2006-06-29

Review 3.  Assessment of cerebrospinal fluid outflow resistance.

Authors:  Anders Eklund; Peter Smielewski; Iain Chambers; Noam Alperin; Jan Malm; Marek Czosnyka; Anthony Marmarou
Journal:  Med Biol Eng Comput       Date:  2007-07-17       Impact factor: 2.602

4.  Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA).

Authors:  Johannes Lemcke; Ullrich Meier; Cornelia Müller; Michael J Fritsch; Uwe Kehler; Niels Langer; Michael Kiefer; Regina Eymann; Martin U Schuhmann; Andreas Speil; Friedrich Weber; Victor Remenez; Veit Rohde; Hans-Christoph Ludwig; Dirk Stengel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-01       Impact factor: 10.154

5.  Cerebrospinal fluid dynamics in non-acute post-traumatic ventriculomegaly.

Authors:  Afroditi D Lalou; Virginia Levrini; Marek Czosnyka; Laurent Gergelé; Matthew Garnett; Angelos Kolias; Peter J Hutchinson; Zofia Czosnyka
Journal:  Fluids Barriers CNS       Date:  2020-03-30

Review 6.  Clinical predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis.

Authors:  Santhosh G Thavarajasingam; Mahmoud El-Khatib; Mark Rea; Salvatore Russo; Johannes Lemcke; Lana Al-Nusair; Peter Vajkoczy
Journal:  Acta Neurochir (Wien)       Date:  2021-07-08       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.